Article Text

SAT0359 Aligning Clinical Trials in Rheumatoid Arthritis with Real-Life Populations
  1. N.C. Navarro Coy1,2,
  2. R.M. West3,
  3. S.H. Pavitt4,
  4. K. Hyrich5,
  5. D. Veale6,
  6. P. Emery1,2,
  7. M.H. Buch1,2
  1. 1Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds
  2. 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust
  3. 3Leeds Institute of Health Sciences
  4. 4School of Dentistry, University of Leeds, Leeds
  5. 5Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
  6. 6Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland


Background Despite the huge benefits of biologics in the treatment of rheumatoid arthritis (RA), the level of success reported in Randomised Controlled Trials (RCTs) is not achieved in standard practice (1-5).

Objectives To establish the level of discrepancy in biologic-naïve cohorts between RCTs and the standard RA population from two local registries (Leeds and Dublin) focusing in particular on patient characteristics.

Methods A comprehensive literature review was undertaken to identify all published RCTs in biologic-naïve RA patients. The characteristics of patients recruited to the selected RCTs were collated and summarised. Datasets from biologic-naïve patients consented to the biologics registries at the University of Leeds (BMC) and the University College Dublin (UCD) were also collated and summarised. This allowed the identification of the most common patient characteristics representative of RCTs and the general population in RA. The characteristics of patients from the RCTs were compared to BMC/UCD cohorts.

Results A total of 32 RCTs for biologic-naïve RA patients were identified from the literature review. A total of 1107 datasets from biologic-naïve RA patients were identified from the Leeds (n=684) and Dublin (n=423) registries. The comparison of the patient characteristics from these cohorts showed that patients from RCTs are older than in the registries (mean (SD) age: RCTs=52.6 (2.67); registries=50.9 (15.06); p=0.0001), however more female patients comprise registries (RCTs=66.14%; registries=73.98%). Almost all disease activity components at presentation are higher in RCTs, leading to significantly higher DAS28 score for patients recruited to RCTs (mean (SD) DAS28-CRP=5.59 (0.38); DAS28-ESR=6.56 (0.37)) than those in the registries (mean (SD) DAS28-CRP=5.38 (1.19); DAS28-ESR=5.76 (1.26); p=0.0001)(refer to Table 1). Data on co-morbidities and concomitant drugs is limited in RCTs mainly due to the exclusion criteria that limit the studies population. The data from the registries, albeit incomplete, shows that these patients present with varied co-morbidity, with hypertension (25.9%) being the most common. Other conditions are present in less than 10% of the total.

Conclusions This initial evaluation illustrates that the selected RCT populations are not representative of real-life general biologic-naïve RA population, limiting the applicability of RCTs. The higher disease activity inclusion in RCTs illustrates they are yet to adopt the treat to target strategies in the management of RA. Extending the comparison to a larger, registry-based population would add further insights into the disparity between RCT and real-life populations.


  1. Zink A, et al. Arthritis Rheum 2006.

  2. Krishan E, et al. Arthritis Res Ther 2004.

  3. Visman IM, et al. J Rheumatol 2011.

  4. Kievit W, et al. Ann Rheum Dis 2007.

  5. Curtis JR, et al. Semin Arthritis Rheum 2010.

Acknowledgements The “BeTheCure” project as part of the Innovative Medicines Initiative Joint Undertaking, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Disclosure of Interest N. Navarro Coy: None declared, R. West: None declared, S. Pavitt: None declared, K. Hyrich: None declared, D. Veale: None declared, P. Emery Grant/research support from: Abbvie, Bristol-Myers-Squibb, MSD, Roche-Chugai, Pfizer, UCB, Novartis and Lilly, Consultant for: Abbvie, Bristol-Myers-Squibb, MSD, Roche-Chugai, Pfizer, UCB, Novartis and Lilly, M. Buch Grant/research support from: Abbvie, Bristol-Myers-Squibb, Roche-Chugai, Pfizer and UCB, Consultant for: Abbvie, Bristol-Myers-Squibb, Roche-Chugai, Pfizer and UCB

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.